Oscotec Inc.
↗Seongnam-si, South Korea
Oscotec Inc. is a South Korean clinical-stage biotechnology company founded in 1998. The company focuses on the discovery and development of small molecule therapeutics for oncology and immunology, as well as the manufacturing of dental bone graft materials and functional ingredients.
Oscotec has gained significant industry recognition for its role in the development of Lazertinib (marketed as Leclaza/Lazcluze), a third-generation EGFR inhibitor for non-small cell lung cancer, which was licensed to Yuhan Corporation and further developed in partnership with Janssen. The company is currently advancing a pipeline of novel candidates targeting chemotherapy resistance and neurodegenerative diseases, including an Alzheimer's program licensed to Sanofi.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$50M-$100M
Founded:1998
Ownership:public
Status:operating
FUNDING
Investors:Tiger Asset Management Investment Co. Ltd.
STOCK
Exchange:KOSDAQ
Ticker:039200
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (Lazertinib)
Modalities:Small molecule, Monoclonal antibody
Active Trials:10
Trial Phases:Phase 1: 3 | Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Genosco
Key Partnerships:Yuhan Corporation (Lazertinib), Janssen (Lazertinib), Sanofi (ADEL-Y01 Alzheimer's candidate), ADEL (Co-development of ADEL-Y01)
COMPETITION
Position:Emerging
Competitors:Moderna, Jazz Pharmaceuticals, BeiGene
LEADERSHIP
Key Executives:
Tae-Young Yun - CEO
Kim Jung-kun - CEO
Board Members:Sang-Hyeon Lee, Tae-Young Yun
LINKS
Website:oscotec.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Oscotec Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Oscotec Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.